Oncology Meeting Resources

Personalised Medicine 2013 - Signalling Pathways

01 Mar - 03 Mar, Sitges, Spain

Signalling Pathways 2014

Please find below the links to all Signalling Pathways in Cancer 2013 presentations that have an abstract, slide set or webcast. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Search Meeting Resources by Keyword

 

 

Useful links

Presenter Presentation title Session title
Jean-Yves Douillard ESMO Educational activities: From past to future. Focus on personalized medicine Introduction
Yossi Yarden The principles of signal transduction (focus on concepts of signalling, perturbation, opportunities for intervention) The basis of targeted therapy
Giampaolo Tortora Mechanisms of primary and secondary resistance The basis of targeted therapy
Joaquin Arribas Conventional preclinical models (focus on classical in vitro and in vivo models including transgenics) Pre-clinical models
Livio Trusolino Tumor patient derived models (“xenopatients”) Pre-clinical models
Aleix Prat Characterization of one disease in different subtypes (breast cancer as an example) Dissecting the field of biomarkers
Federico Rojo Pitfalls and challenges with tumor tissue specimens Dissecting the field of biomarkers
Giuseppe Curigliano Tumor-host interaction: Focus on immune response and microenvironment Dissecting the field of biomarkers
Fortunato Ciardiello Pharmacology basis of targeted therapy Clinical pharmacology concepts of targeted therapy
Josep Tabernero How to maximize smart clinical development from phase I Clinical pharmacology concepts of targeted therapy
Andres Cervantes Ruiperez ESMO Guidelines: How deep we go in personalized medicine Guidelines
Enriqueta Felip Current characterization of lung cancer (focus on pathological and molecular subtypes) Lung cancer
Benjamin Besse First generation EGFR inhibitors, the breakthrough in stratified medicine in lung cancer Lung cancer
Rolf A. Stahel New EGFR inhibitors: The cutting-edge frontier Lung cancer
Solange Peters HER2/neu in non-small cell lung cancer Lung cancer